Polpharma Biologics Rebrands As New Warsaw Site Is Validated

First Production Run Expected In Mid-2021

As it gears up to begin production at its new clinical and commercial manufacturing site in Warsaw, Polpharma Biologics has announced a new logo and corporate message to mark a year of “significant growth.”

Europe
Polpharma Biologics recently brought under its brand the Bioceros R&D site in Utrecht • Source: Shutterstock

More from Biosimilars

More from Products